Lataa...
A thorough QTc study demonstrates that olmesartan medoxomil does not prolong the QTc interval
Two studies (ROADMAP and ORIENT) evaluating the renoprotective effects of olmesartan medoxomil (OM) in patients with type 2 diabetes suggested OM is associated with increased cardiovascular mortality. We conducted a thorough QTc study to evaluate the effects of OM on cardiac repolarization. A random...
Tallennettuna:
| Julkaisussa: | J Clin Pharmacol |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
John Wiley and Sons Inc.
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5063153/ https://ncbi.nlm.nih.gov/pubmed/26239632 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.610 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|